Development of targeted SARS-CoV-2 antivirals

Eisbach Bio receives 6.7 million Euros grant from the Bavarian Government

10-Nov-2021 - Eisbach Bio, a biotechnology startup targeting the molecular machines that drive human disease, already received funding of 8 million euros from the German Federal Ministry of Education and Research (BMBF) in July 2021. At the end of October 2021, the start-up announces another financial support ...

Exploiting deep learning to develop sustainable COVID-19 inhibitors

Collaboration Eisbach Bio GmbH & Technische Universität Kaiserslautern

10-Sep-2021 - Eisbach Bio GmbH and the team of Prof. Dr.-Ing. Naim Bajcinca from the Technische Universität Kaiserlautern (TUK) announce a collaboration where they will use deep learning to track and trace arising mutations in the genome of SARS-CoV-2 and develop sustainable small molecule inhibitors that will ...

Eisbach Bio receives EUR 8 million government grant to progress COVID-19 antiviral through Phase I/II clinical development

22-Jul-2021 - Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, announced additional financial support from the German Ministry for Education and Research (BMBF) for the clinical development of its first-in-class SARS-CoV-2 helicase inhibitor. The total funding of ...